U.S. launches tariff probe into Germany's drug pricing

• Germany proposed overhauling its health insurance system in April to reduce public health spending, including higher discounts for insurance funds from the pharma industry
• The investigation uses Section 301 of the Trade Act, which allows unilateral U.S. action against countries with unfair trade practices that burden American commerce
• Multiple pharmaceutical companies have warned they might withdraw or delay new medicines in Germany in response to the proposed cost-saving legislation

Summary: U.S. Launches Tariff Probe into Germany's Drug Pricing

The United States has initiated a Section 301 Trade Act investigation into Germany's pharmaceutical pricing policies, citing "persistent underpayment" for medicines that allegedly discriminates against U.S. drugmakers. The probe was announced in late Thursday statements from U.S. Trade Representative officials.

Key Details:

• Investigation focuses on whether Germany's cost-reduction measures unfairly burden American pharmaceutical companies and U.S. commerce
• Trump administration argues American patients are shouldering a "disproportionate" share of global drug costs while other countries pay less
• Section 301 authority allows the U.S. to take unilateral action against trading partners deemed to have unfair practices

Germany's Healthcare Reforms:

In April, Germany proposed overhauling its health insurance system to control rising healthcare expenditures and reduce pressure on public finances. The draft legislation includes cost-saving measures such as higher mandatory discounts for insurance funds from pharmaceutical companies. Multiple drugmakers have reportedly threatened to withdraw or delay new medicines in Germany in response.

Market Implications:

The investigation heightens trade tensions between the U.S. and Europe, specifically targeting healthcare policy. U.S. pharmaceutical companies could benefit if Germany is pressured to increase drug reimbursement rates. The Trump administration has previously introduced "Most Favored Nation" (MFN) policies linking U.S. drug prices to lower international prices.

The German Health Ministry has not yet responded to requests for comment. The legislation under scrutiny is currently proceeding through Germany's parliamentary process, with U.S. officials expressing particular concern about the "fast-tracking" of measures that would further reduce pharmaceutical spending.